Literature DB >> 33874930

Patent foramen ovale revealed by COVID-19 pneumonia.

Charlotte Vanhomwegen1, Olivier Taton2, Nicolas Selvais3, Olivier Vanhove2, Dimitri Leduc2.   

Abstract

BACKGROUND: Platypnea-orthodeoxia syndrome (POS) is a rare condition characterized by dyspnoea (platypnea) and arterial desaturation in the upright position resolved in the supine position (orthodeoxia). Intracardiac shunt, pulmonary ventilation-perfusion mismatch and others intrapulmonary abnormalities are involved. CASE
PRESENTATION: We report a case of POS associated with two pathophysiological issues: one, cardiac POS caused by a patent foramen ovale (PFO) and second, pulmonary POS due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interstitial pneumonia. POS has resolved after recovery of coronavirus disease 2019 (COVID-19) pneumonia.
CONCLUSIONS: Right-to-left interatrial shunt and intrapulmonary shunt caused by SARS-CoV-2 pneumonia contributed to refractory hypoxemia and POS. Therefore, in case of COVID-19 patient with unexplained POS, the existence of PFO must be investigated.

Entities:  

Keywords:  Hypoxemia; Patent foramen ovale; Pulmonary vasoconstriction; SARS-CoV-2; Ventilation inhomogeneity

Year:  2021        PMID: 33874930     DOI: 10.1186/s12890-021-01494-7

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.317


  3 in total

1.  Acute heart failure : An unmet medical need.

Authors:  A G Rigopoulos; C Bakogiannis; R de Vecchis; S Sakellaropoulos; M Ali; M Teren; M Matiakis; C Tschoepe; M Noutsias
Journal:  Herz       Date:  2017-09-22       Impact factor: 1.443

2.  COVID-19 May Be Exacerbated by Right-to-Left Interatrial Shunt.

Authors:  Rajkumar Rajendram; G Abbas Kharal; Rishi Puri
Journal:  Ann Thorac Surg       Date:  2020-05-31       Impact factor: 4.330

3.  Rethinking the respiratory paradigm of COVID-19: a 'hole' in the argument.

Authors:  Rajkumar Rajendram; Ghulam Abbas Kharal; Naveed Mahmood; Rishi Puri; Mubashar Kharal
Journal:  Intensive Care Med       Date:  2020-06-02       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.